NTLA (STOCKS)
Intellia Therapeutics, Inc
$14.700000
+0.440000 (+3.09%)
Prev close: $14.260000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- John M. Leonard
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,743.66M
- Employees
- 598
- P/E (TTM)
- -3.73
- P/B (TTM)
- 2.47
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
11
Buy
11
Hold
2
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.83 | $-0.97 | +0.1439 | +14.78% |
|
Sep 2025 (Q3)
|
$-0.92 | $-1.02 | +0.1019 | +9.97% |
|
Jun 2025 (Q2)
|
$-0.98 | $-1.04 | +0.0582 | +5.61% |
|
Mar 2025 (Q1)
|
$-1.10 | $-1.31 | +0.2082 | +15.92% |
Financial Statements
| Revenues | $67.67M |
| Benefits Costs and Expenses | $480.37M |
| Costs And Expenses | $508.66M |
| Operating Expenses | $508.66M |
| Research and Development | $388.86M |
| Other Operating Expenses | $119.80M |
| Operating Income/Loss | -$440.99M |
| Income/Loss From Continuing Operations After Tax | -$412.69M |
| Income/Loss From Continuing Operations Before Tax | -$412.69M |
| Income/Loss From Equity Method Investments | $0.00 |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$412.69M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$412.69M |
| Net Income/Loss Available To Common Stockholders, Basic | -$412.69M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.81 |
| Diluted Earnings Per Share | -$3.81 |
| Basic Average Shares | 108,376,000 |
| Diluted Average Shares | 108,376,000 |
| Assets | $842.13M |
| Current Assets | $527.71M |
| Noncurrent Assets | $314.42M |
| Fixed Assets | $17.67M |
| Other Non-current Assets | $296.75M |
| Liabilities | $170.73M |
| Current Liabilities | $103.88M |
| Accounts Payable | $20.25M |
| Wages | $23.07M |
| Other Current Liabilities | $60.56M |
| Noncurrent Liabilities | $66.85M |
| Equity | $671.39M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $671.39M |
| Liabilities And Equity | $842.13M |
| Net Cash Flow From Operating Activities | -$394.74M |
| Net Cash Flow From Operating Activities, Continuing | -$394.74M |
| Net Cash Flow From Investing Activities | $228.03M |
| Net Cash Flow From Investing Activities, Continuing | $228.03M |
| Net Cash Flow From Financing Activities | $131.49M |
| Net Cash Flow From Financing Activities, Continuing | $131.49M |
| Net Cash Flow | -$35.22M |
| Net Cash Flow, Continuing | -$35.22M |
| Comprehensive Income/Loss | -$412.27M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$412.27M |
| Other Comprehensive Income/Loss | $427.00K |